Prospective Evaluation Plan for Randomised Trials of Prostate Cancer Screening

To enable pooled analyses of continuing and planned randomised trials of prostate cancer screening, guidelines for minimal data required for such analyses were developed in the recent meeting of the International Prostate Screening Trial Evaluation Group (IPSTEG). The aim of the pooled analysis with data on individual level will be: Estimation of the effect of screening on prostate cancer mortality with greater precision than individual studies Assessment of optimal screening procedures and interval Identification of subgroups within the populations that might receive most benefit from screening Evaluation of the quality of life effects and cost effectiveness of screening. All studies included in the combined analysis share a common core protocol with minimum data requirements. The protocol allows, however, adaptation of the procedures to local circumstances within defined options It should be noted that the process is continuing and the protocol is subject to evaluation and revision in the meetings of the IPSTEG on a regular basis. It should be noted that the process continuing and the protocol is subject evaluation and revision in the meetings the IPSTEG on a regular basis.

[1]  J. Larson.  The MOS 36-Item Short form Health Survey , 1997, Evaluation & the health professions.

[2]  B. G. Blijenberg,et al.  European randomized study of screening for prostate cancer—The Rotterdam pilot studies , 1996, International journal of cancer.

[3]  C Parkes,et al.  Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer , 1995, BMJ.

[4]  H. D. de Koning,et al.  European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam Pilot studies , 1995, Cancer.

[5]  J. Gohagan,et al.  The prostate, lung, colorectal, and ovarian cancer screening trial of the national cancer institute , 1995 .

[6]  G P Murphy,et al.  Report of the consensus workshop on screening and global strategy for prostate cancer , 1995, Cancer.

[7]  A S Whittemore,et al.  Prostate-specific antigen as predictor of prostate cancer in black men and white men. , 1995, Journal of the National Cancer Institute.

[8]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[9]  I. Thompson,et al.  Chemoprevention of prostate cancer. , 2003, Urology.

[10]  P. Knekt,et al.  Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.

[11]  J. Richie,et al.  Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. , 1994, The Journal of urology.

[12]  R. Kane,et al.  Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age‐referenced PSA, PSA density, and PSA change , 1994, Cancer.

[13]  H. Adami,et al.  Ethics of a prostate cancer screening trial , 1994, The Lancet.

[14]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[15]  E. Greenberg,et al.  Changes in prostate cancer incidence and treatment in USA , 1994, The Lancet.

[16]  N. Wald,et al.  Report of the European Society for Mastology Breast Cancer Screening Evaluation Committee (1993) , 1993 .

[17]  R. Kane,et al.  Characteristics of prostate cancers detected in a multimodality early detection program , 1993 .

[18]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[19]  C G Chute,et al.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.

[20]  W. Ellis,et al.  The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma. , 1993, The Journal of urology.

[21]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[22]  I. Thompson,et al.  Disease-specific survival following routine prostate cancer screening by digital rectal examination. , 1993, JAMA.

[23]  P. Boyle,et al.  Screening for prostate cancer--necessity or nonsense? , 1993, European journal of cancer.

[24]  Franciscus M. Bentvelsen,et al.  Modalities available for screening for prostate cancer. , 1993, European journal of cancer.

[25]  A. Engeland,et al.  Prostate-specific antigen in serum from blood donors with subsequent prostate cancer diagnosis. , 1993, European journal of cancer.

[26]  R. Kane,et al.  The relationship of prostate‐specific antigen to digital rectal examination and transrectal ultrasonography: Findings of the American cancer society national prostate cancer detection project , 2010, Cancer.

[27]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[28]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[29]  J. Goméz,et al.  Serum prostate specific antigen as pre-screening test for prostate cancer. , 1992, The Journal of urology.

[30]  K. Helzlsouer,et al.  Prostate-specific antigen levels and subsequent prostate cancer: potential for screening. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[31]  R. Hiatt,et al.  Case-control study of screening for prostatic cancer by digital rectal examinations , 1991, The Lancet.

[32]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[33]  Norman E. Breslow,et al.  Statistical Methods in Cancer Research, Vol. II: The Design and Analysis of Cohort Studies. , 1990 .

[34]  S. Torp-Pedersen,et al.  Prostate Cancer: Comparison of Transrectal US and Digital Rectal Examination for Screening , 1988, Radiology.

[35]  The management of clinically localized prostate cancer. , 1987, National Institutes of Health consensus development conference consensus statement.

[36]  M. Blute,et al.  Long-term followup of young patients with stage A adenocarcinoma of the prostate. , 1986, The Journal of urology.

[37]  H. Watanabe,et al.  Comparison of digital examination and transrectal ultrasonography for the diagnosis of prostatic cancer. , 1986, The Journal of urology.